Drug profile · INN
dexbrompheniramine maleate
BROMPHERIL
dexbrompheniramine maleate (BROMPHERIL) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — dexbrompheniramine maleate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dexbrompheniramine maleate (BROMPHERIL) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dexbrompheniramine maleate?
dexbrompheniramine maleate (BROMPHERIL) is a histamine h1 receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dexbrompheniramine maleate?
BROMPHERIL is a marketed brand name for dexbrompheniramine maleate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dexbrompheniramine maleate?
dexbrompheniramine maleate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.